Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 113 articles:
HTML format
Text format



Single Articles


    March 2017
  1. CEPEDA JA, Thomas DL, Astemborski J, Sulkowski MS, et al
    Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study.
    Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  2. NAGGIE S, Marks KM, Hughes M, Fierer DS, et al
    Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
    Clin Infect Dis. 2017 Feb 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. ANDERSON ES, Galbraith JW, Deering LJ, Pfeil SK, et al
    Continuum of Care for HCV Among Patients Diagnosed in the Emergency Department Setting.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed     Text format    


  4. LO RE V
    Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.
    Clin Infect Dis. 2017;64:498-500.
    PubMed     Text format    


  5. KOVARI H, Rauch A, Kouyos R, Rougemont M, et al
    Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2017;64:490-497.
    PubMed     Text format    


  6. BLOCK TM, Locarnini S, McMahon BJ, Rehermann B, et al
    Use of current and new endpoints in the evaluation of experimental hepatitis B therapeutics.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  7. YOUNG J, Rossi C, Gill J, Walmsley S, et al
    Risk factors for hepatitis C virus reinfection after sustained virologic response in patients co-infected with HIV.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  8. BHATTACHARYA D, Belperio PS, Shahoumian TA, Loomis TP, et al
    Effectiveness of All-Oral Antiviral Regimens in 996 Genotype 1 HIV/HCV Coinfected Patients Treated in Routine Practice.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  9. BURTON MJ, Naggie S
    Real World Effectiveness of DAA Therapies in HIV/HCV Co-Infection: 996 Veterans Can't Be Wrong.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  10. BEGUELIN C, Friolet N, Moradpour D, Sahli R, et al
    Impact of tenofovir on hepatitis delta virus replication in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  11. ANDREONI M, Teti E, Antinori A, Milazzoi L, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program.
    Clin Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


  12. VEENHUIS RT, Astemborski J, Chattergoon MA, Greenwood P, et al
    Systemic Elevation of Proinflammatory Interleukin-18 in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Coinfection Versus HIV or HCV Monoinfection.
    Clin Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


    January 2017
  13. RIVERO-JUAREZ A, Frias M, Lopez-Lopez P, Risalde ML, et al
    Hepatitis E virus infection in anti-HEV IgG-carryinfing patients after successful HCV treatment: reactivation or reinfection?
    Clin Infect Dis. 2017 Jan 11. pii: cix004. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  14. MASSIMO A, Teti E, Antinori A, Milazzoi L, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program.
    Clin Infect Dis. 2016 Dec 22. pii: ciw846. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. LO RE V 3RD
    Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  16. KOVARI H, Rauch A, Kouyos R, Rougemont M, et al
    Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  17. FORD MM, Johnson N, Desai P, Rude E, et al
    From Care to Cure: Demonstrating a Model of Clinical Patient Navigation for Hepatitis C Care and Treatment in High-Need Patients.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  18. VEENHUIS RT, Astemborski J, Chattergoon MA, Greenwood P, et al
    Systemic Elevation of Proinflammatory Interleukin 18 in HIV/HCV Coinfection versus HIV or HCV Monoinfection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    November 2016
  19. LIEVELD FI, Arends JE, Amelung L, Dijk E, et al
    Overcoming Outpatient Loss to Follow-up as a Barrier to Efficiently Instituting Hepatitis B Liver-related Care.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  20. FOSTER AL, Gaisa MM, Hijdra RM, Turner SS, et al
    Shedding of Hepatitis C Virus Into the Rectum of HIV-infected Men Who Have Sex With Men.
    Clin Infect Dis. 2016 Nov 9. pii: ciw740. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. BAROCAS JA, Linas BP
    Decision Science at Work: The Case of Hepatitis C Virus Postexposure Prophylaxis.
    Clin Infect Dis. 2016.
    PubMed     Text format    


    October 2016
  22. SARRAZIN C, Isakov V, Svarovskaia E, Hedskog C, et al
    Late relapse versus HCV reinfection in patients with sustained virologic response after sofosbuvir-based therapies.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    September 2016
  23. NAGGIE S, Holland D, Sulkowski MS, Thomas DL, et al
    HCV post-exposure prophylaxis in the healthcare worker: Why DAAs don't change a thing.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  24. MOORE MS, Ivanina E, Bornschlegel K, Qiao B, et al
    Hepatocellular Carcinoma and Viral Hepatitis in New York City.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  25. GREBELY J, Dore GJ, Zeuzem S, Aspinall RJ, et al
    Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of Phase 3 ASTRAL trials.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  26. GREBELY J, Mauss S, Brown A, Bronowicki JP, et al
    Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  27. INGILIZ P, Christensen S, Kimhofer T, Hueppe D, et al
    Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus infection in HCV-mono-infected and HIV-HCV co-infected individuals - Results from the German hepatitis C cohort (GECCO-01).
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  28. KLEVENS RM, Canary L, Huang X, Denniston MM, et al
    The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  29. KLEIN MB, Althoff KN, Jing Y, Lau B, et al
    Risk of endstage liver disease in HIV-viral hepatitis co-infected persons in North America from the early to modern antiretroviral therapy eras.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  30. ABRAVANEL F, Metivier S, Chauveau M, Peron JM, et al
    Transmission of HCV NS5A inhibitor-resistant variants among HIV-infected men who have sex with men.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  31. KAMSTRA R, Azoulay L, Steele R, Klein MB, et al
    Hospitalizations in immigrants and non-immigrants diagnosed with chronic hepatitis C infection in Quebec.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  32. SPRADLING PR, Xing J, Rupp LB, Moorman AC, et al
    Infrequent clinical assessment of chronic hepatitis B patients in United States general healthcare settings.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  33. MCMAHON BJ
    Sliding Down the Cascade of Care for Chronic Hepatitis B Virus Infection.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  34. SULKOWSKI MS, Chuang WL, Kao JH, Yang JC, et al
    No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    July 2016
  35. YOUNOSSI ZM, Stepanova M, Sulkowski M, Foster GR, et al
    Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and 3 Clinical Trials.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available



  36. Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  37. WYLES DL, Sulkowski MS, Dieterich D
    Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.
    Clin Infect Dis. 2016;63 Suppl 1:S3-S11.
    PubMed     Text format     Abstract available


  38. MACBRAYNE CE, Kiser JJ
    Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.
    Clin Infect Dis. 2016;63 Suppl 1:S12-23.
    PubMed     Text format     Abstract available


  39. ROWAN SE, Rogers M, Bayer J, Smith L, et al
    Treatment of HCV in HIV coinfected individuals in real world clinical settings: results from two large HIV care clinics.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  40. AL-KINDI SG, Zidar DA, McComsey GA, Longenecker CT, et al
    Gender differences in statin prescription rate among patients living with HIV and HCV.
    Clin Infect Dis. 2016.
    PubMed     Text format    


    June 2016
  41. FEDELI U, Schievano E
    Mortality waves related to Hepatitis C virus infection: multiple causes of death data from the US and Northern Italy compared.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  42. FELD JJ, Maan R, Zeuzem S, Kuo A, et al
    Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  43. SOGNI P, Gilbert C, Lacombe K, Piroth L, et al
    All-oral DAA regimens in HIV-HCV coinfected cirrhotic patients are efficient and safe. Real-life results from the prospective ANRS CO13 - HEPAVIH cohort.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  44. GJAERDE LI, Shepherd L, Jablonowska E, Lazzarin A, et al
    Trends in incidences and risk factors for hepatocellular carcinoma and other liver events in HIV and hepatitis C virus co-infected individuals from 2001 to 2014: a multi-cohort study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  45. HEDENSTIERNA M, Nangarhari A, Weiland O, Aleman S, et al
    Diabetes and cirrhosis are risk factors for hepatocellular carcinoma after successful treatment of chronic hepatitis C.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  46. WILSON EM, Tang L, Kottilil S
    Eradication Strategies for Chronic Hepatitis B Infection.
    Clin Infect Dis. 2016;62 Suppl 4:S318-25.
    PubMed     Text format     Abstract available


  47. TRAN TT
    Hepatitis B in Pregnancy.
    Clin Infect Dis. 2016;62 Suppl 4:S314-7.
    PubMed     Text format     Abstract available


  48. GONZALEZ SA, Perrillo RP
    Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy.
    Clin Infect Dis. 2016;62 Suppl 4:S306-13.
    PubMed     Text format     Abstract available


  49. WONG GL, Wong VW, Chan HL
    Virus and Host Testing to Manage Chronic Hepatitis B.
    Clin Infect Dis. 2016;62 Suppl 4:S298-305.
    PubMed     Text format     Abstract available


  50. SHANKAR H, Blanas D, Bichoupan K, Ndiaye D, et al
    A Novel Collaborative Community-Based Hepatitis B Screening and Linkage to Care Program for African Immigrants.
    Clin Infect Dis. 2016;62 Suppl 4:S289-97.
    PubMed     Text format     Abstract available


  51. DANDRI M, Petersen J
    Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.
    Clin Infect Dis. 2016;62 Suppl 4:S281-8.
    PubMed     Text format     Abstract available


    May 2016
  52. COOPER C, Naggie S, Saag M, Yang JC, et al
    Successful Retreatment of HCV in Patients Coinfected with HIV Who Failed 12 Weeks of Ledipasvir/Sofosbuvir.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  53. KELLY EM, Dodge JL, Sarkar M, French AL, et al
    Marijuana Use is not Associated with Progression to Advanced Liver Fibrosis in HIV/HCV Coinfected Women.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  54. SOLLIMA S, D'Avolio A, Cattaneo D, Micheli V, et al
    Darunavir-based antiretroviral therapy may affect the efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir in HCV/HIV-1 coinfected patients.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  55. CLEMENT ME, Park LP, Navar AM, Okeke NL, et al
    Statin Utilization and Recommendations Among HIV and HCV-Infected Veterans: A Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    April 2016
  56. KANWAL F, Kramer JR, El-Serag HB, Frayne S, et al
    Race and gender differences in the use of direct acting antiviral agents for HCV.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  57. NICOLAS D, Esteve A, Cuadros A, Campbell CN, et al
    Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  58. RAMSAY I, Gorton RL, Patel M, Workman S, et al
    Transmission of Hepatitis B core Antibody and Galactomannan Enzyme Immunoassay positivity via immunoglobulin products: a comprehensive analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  59. SHAFRAN SD
    Reply to Menard et al.
    Clin Infect Dis. 2016;62:949-50.
    PubMed     Text format    


    March 2016
  60. LUETKEMEYER AF, McDonald C, Ramgopal M, Noviello S, et al
    12 Weeks of Daclatasvir in Combination with Sofosbuvir for HIV-HCV Coinfection (ALLY-2 study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  61. RIVERO-JUAREZ A, Frias M, Rodriguez-Cano D, Cuenca-Lopez F, et al
    Isolation of Hepatitis E virus from breast milk during acute infection.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  62. TOSTI ME, Alfonsi V, Lacorte E, Mele A, et al
    Acute hepatitis B after the implementation of universal vaccination in Italy: results from a 22-years surveillance (1993-2014).
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  63. LY KN, Hughes EM, Jiles RB, Holmberg SD, et al
    Rising Mortality Associated with Hepatitis C Virus in the United States, 2003-2013.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  64. DEL BELLO D, Cha A, Sorbera M, Bichoupan K, et al
    Real-world Sustained Virologic Response Rates of Sofosbuvir-containing Regimens in Patients Coinfected with Hepatitis C and HIV.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    February 2016
  65. HSIEH YH, Rothman RE, Laeyendecker OB, Kelen GD, et al
    Evaluation of The CDC Recommendations for HCV Testing in an Urban Emergency Department.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  66. LYONS MS, Kunnathur VA, Rouster SD, Hart KW, et al
    Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  67. MARTIN NK, Thornton A, Hickman M, Sabin C, et al
    Can HCV direct-acting antiviral treatment as prevention reverse the HCV epidemic amongst men who have sex with men in the UK - epidemiological and modelling insights.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  68. JONAS MC, Rodriguez CV, Redd J, Sloane DA, et al
    Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  69. HARRINGTON PR, Fleischer R, Connelly SM, Lewis LL, et al
    Reply to Merli et al.
    Clin Infect Dis. 2016;62:528-9.
    PubMed     Text format    


  70. VERMEHREN J, Maasoumy B, Maan R, Cloherty G, et al
    Applicability of HCV RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C genotype 1 infection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    January 2016
  71. KUNCIO DE, Newbern EC, Johnson CC, Viner KM, et al
    Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C-Positive Women.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  72. SIMMONS B, Saleem J, Hill A, Riley RD, et al
    Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  73. SAEED S, Strumpf EC, Walmsley S, Rollet-Kurhajec K, et al
    How generalizable are the results from trials of Direct Antiviral Agents to people coinfected with HIV/Hepatitis C virus in the real world?
    Clin Infect Dis. 2016 Jan 6. pii: civ1222.
    PubMed     Text format     Abstract available


  74. MARTINELLO M, Dore GJ
    HCV direct-acting antivirals in the "real world": Efficacy comparable to clinical trials.
    Clin Infect Dis. 2016 Jan 6. pii: civ1227.
    PubMed     Text format    


  75. MENARD A, Colson P, Catherine D, Isabelle R, et al
    First real life evidence of new direct-acting antivirals (DAA) in co-infected HIV HCV patients: better than ever.
    Clin Infect Dis. 2016 Jan 5. pii: civ1215.
    PubMed     Text format    


  76. KHATRI A, Dutta S, Wang H, Podsadecki T, et al
    Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
    Clin Infect Dis. 2016 Jan 5. pii: civ1213.
    PubMed     Text format     Abstract available


  77. STOCKDALE AJ, Geretti AM
    Reply to Boyd and Lacombe.
    Clin Infect Dis. 2016;62:130-1.
    PubMed     Text format    


  78. KESHTKAR-JAHROMI M, Rassaei N, Bruno MA, Maneval ML, et al
    Photo Quiz. A 59-Year-Old Man With Multiple Liver Lesions, Rash, and Uveitis.
    Clin Infect Dis. 2016;62:82-3.
    PubMed     Text format    


    November 2015
  79. DURHAM DP, Skrip LA, Bruce RD, Vilarinho S, et al
    The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  80. DONNELLY JP, Franco R, Wang HE, Galbraith JW, et al
    Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  81. HONER ZU SIEDERDISSEN C, Maasoumy B, Marra F, Deterding K, et al
    Drug-drug interactions with novel all oral interferon free antiviral agents in a large real-world cohort.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    October 2015
  82. WILSON EM, Kattakuzhy S, Sidharthan S, Sims Z, et al
    Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  83. MERLI M, Messina E, Salpietro S, Lazzarin A, et al
    Marked decrease in lymphocyte count in HIV/HCV co-infected patients with advanced liver disease during anti-HCV treatment with direct-acting antiviral regimens including ribavirin.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  84. KATTAKUZHY S, Wilson E, Sidharthan S, Sims Z, et al
    Six-week Combination Directly Acting Anti-HCV Therapy Induces Moderate Rates of Sustained Virologic Response in Patients with Advanced Liver Disease.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  85. ZHANG Q, Qi W, Wang X, Zhang Y, et al
    Epidemiology of hepatitis B and C infections and benefits of programs for hepatitis prevention in northeastern China: A cross-sectional study.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  86. GUILLOIS Y, Abravanel F, Miura T, Pavio N, et al
    High proportion of asymptomatic infections in an outbreak of hepatitis E associated with a spit-roasted piglet, France, 2013.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    September 2015
  87. XU F, Moorman AC, Tong X, Gordon SC, et al
    All-cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  88. BRUNET L, Moodie EE, Young J, Cox J, et al
    Progression of liver fibrosis and modern combination antiretroviral therapy regimens in HIV-hepatitis C co-infected persons.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  89. BUTI M, Gordon SC, Zuckerman E, Lawitz E, et al
    Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  90. BOYD A, Lacombe K
    More long-term assessment of transient elastography is needed for HIV-HBV co-infected patients undergoing treatment with tenofovir.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  91. BALAGOPAL A, Thomas DL
    Editorial Commentary: Who is "Special" Now?
    Clin Infect Dis. 2015;61:826-8.
    PubMed     Text format    


    August 2015
  92. SIDHARTHAN S, Kohli A, Kottilil S
    Reply to Harrington et al.
    Clin Infect Dis. 2015;61:667-8.
    PubMed     Text format    


  93. TROOSKIN SB, Reynolds H, Kostman JR
    Access to Costly New Hepatitis C Drugs: Medicine, Money and Advocacy.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  94. MESSORI A
    Newest treatments for hepatitis C: how can we manage sustainability?
    Clin Infect Dis. 2015.
    PubMed     Text format    


  95. HEARN B, Chasan R, Bichoupan K, Suprun M, et al
    Low Adherence of HIV Providers to Practice Guidelines for Hepatocellular Carcinoma Screening in HIV/Hepatitis B Co-infection.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    July 2015
  96. LAGASCA AM, Kan VL
    Hepatitis C Treatment at a VA Medical Center After the Availability of Directly Acting Agents: Things are Looking Up.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  97. SEABERG EC, Witt MD, Jacobson LP, Detels R, et al
    Spontaneous clearance of the hepatitis C virus among men who have sex with men.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  98. WENZLER E, Dickson W, Vibhakar S, Adeyemi OM, et al
    Hepatitis C Management and the Infectious Diseases Pharmacist.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  99. STARK JE
    Potential for a Significant Interaction Between Clopidogrel and Dasabuvir.
    Clin Infect Dis. 2015;61:134-5.
    PubMed     Text format    


    June 2015
  100. BALAGOPAL A, Thio CL
    Another Call to Cure Hepatitis B.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  101. COLLINS JM, Raphael KL, Terry C, Cartwright EJ, et al
    Hepatitis B Reactivation During Successful Treatment of Hepatitis C with Sofosbuvir and Simeprevir.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  102. SAWINSKI D, Goldberg D, Blumberg E, Abt PL, et al
    Beyond the NIH Multicenter HIV Transplant Trial Experience: Outcomes of HIV+ liver transplant recipients compared to HCV+ or HIV+/HCV+ co-infected recipients in the United States.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  103. SHAFRAN SD
    HIV Co-infected Have Similar SVR Rates as HCV Mono-infected with DAAs: It's Time to End Segregation and Integrate HIV Patients into HCV Trials.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    May 2015
  104. HARRINGTON PR, Fleischer R, Connelly SM, Lewis LL, et al
    Ribavirin reduces absolute lymphocyte counts in hepatitis C virus infected patients treated with interferon-free direct-acting antiviral regimens.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  105. STOCKDALE AJ, Phillips RO, Beloukas A, Appiah LT, et al
    Liver fibrosis by transient elastography and virologic outcomes after introduction of tenofovir in lamivudine-experienced adults with HIV and hepatitis B virus (HBV) co-infection in Ghana.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  106. HARRINGTON PR, Deming DJ, Komatsu TE, Naeger LK, et al
    Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  107. SIMMONS B, Saleem J, Heath K, Cooke GS, et al
    Long-term treatment outcomes of patients infected with Hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a Sustained Virological Response.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  108. CHASTAIN CA, Beekmann SE, Wallender EK, Hulgan T, et al
    Hepatitis C Management and the Infectious Diseases Physician: A Survey of Current and Anticipated Practice Patterns.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  109. PIROTH L, Paniez H, Taburet AM, Vincent C, et al
    High cure rate with 24 weeks of daclatasvir-based quadruple therapy in treatment-experienced null-responder HIV/HCV genotype 1/4 co-infected patients: the ANRS HC 30 QUADRIH study.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    January 2015
  110. ABRAVANEL F, Lhomme S, Rostaing L, Kamar N, et al
    Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse.
    Clin Infect Dis. 2015;60:96-9.
    PubMed     Text format     Abstract available


    November 2014
  111. ABRAHAM AG, Althoff KN, Jing Y, Estrella MM, et al
    End Stage Renal Disease Among HIV-Infected Adults in North America.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


    October 2014
  112. EHRHARDT S, Xie C, Guo N, Nelson K, et al
    Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


    May 2014
  113. MASHRAGI F, Bernstein RS, Al-Mazroa M, Al-Tawfiq JA, et al
    HIV transmission at a Saudi Arabia hemodialysis unit.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: